BRICANYL
LOE ApproachingNDAINHALATIONAEROSOL, METERED
Approved
Mar 1985
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
2
Data completeness
2/8 — Basic
Drug data last refreshed Yesterday · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
BRICANYL is a terbutaline sulfate metered-dose aerosol inhaler approved in 1985 for respiratory indications. It is a beta-2 adrenergic agonist that works by stimulating bronchial smooth muscle relaxation. The drug is a well-established small molecule indicated for patients requiring rapid bronchodilation.
LOE Approaching
Product approaching loss of exclusivity with moderate competitive pressure (30/100); commercial teams should expect transition planning and defensive strategies.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (2)
Comparing the Efficacy of Bricanyl M2 and Bricanyl M3 at 0.5 and 1.5 mg Dose Levels, to Allow for a Switch From Bricanyl Turbuhaler M2 to Bricanyl Turbuhaler M3
Started Mar 2015
95 enrolled
Asthma
Comparing Symbicort® As-Needed or Bricanyl As-Needed or Pulmicort® Once Daily + Bricanyl As-Needed in Asthma Patients
Started Sep 2009
66 enrolled
Exercise Induced Asthma
Career Relevance
BRICANYL offers limited growth opportunities given its LOE-approaching status and lack of linked job openings. Career value lies in mature brand management, defensive competitive strategy, and transition planning in a stable respiratory franchise.
Brand Manager
Worked on BRICANYL at Sanofi? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.